Teva: A Favored Pharma

Standard & Poor's likes the generic drugmaker's strong pipeline and global presence, and rates the shares a strong buy

Teva Pharmaceutical Industries (TEVA; recent price $43.56) has what we believe to be the broadest product line and most extensive generic drug pipeline in the U.S., as well as a leading generic lineup in other countries. We believe Teva's ability to offer "one-stop shopping" for a wide variety of generic drugs has enabled many of its products to garner leading market shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.